Skip to main content
Equibles
SER logo

SER · Serina Therapeutics, Inc.

Track SER — free

Use SER with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SER

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.47 -0.05 (-1.98%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has concluded that our existing cash and cash equivalents are not expected to be sufficient to fund our operations for the 12 months following the issuance of our unaudited condensed consolidated financial statements for the period ended June 30, 2026, and that substantial doubt about our ability to continue as a going concern continues to exist.”
View the 10-Q filed Aug 13, 2026
Market Cap
$63.25M
Shares
25.40M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.52 Open$2.61 Day$2.52–2.64 52W close$1.28–5.63 Avg vol 30d50K Short int146K · 0.6% float · 2.1d Short vol23% DataMar 2024–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Mar 15, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Very Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg +13%
above
RSI (14) 51
neutral
MACD trend Negative
52-week position 29%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +24%
trailing
6-month return +65%
trailing
YTD return +32%
this year
Relative strength +50%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$19.8K over 90 days · 0% sells
Short interest Falling
0.57% of float · ▼ -34.7% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
27 holders — near 2-yr high, broad support
Squeeze score 45
elevated · 0–100
Fundamentals
Weak
Revenue growth +132%
Y/Y
Gross margin 78%
expanding
EPS growth −26%
Y/Y
Free cash flow $-18.0M
Balance sheet $15.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 138%
annualized · 1-yr
Max drawdown −77%
past year
ATR 7.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
+13% Bullish
RSI (14)
51 Neutral
MACD trend
Negative Bearish
52-week position
29% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$19.8K over 90 days · 0% sells
Short interest Falling
0.57% of float · ▼ -34.7% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
27 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $3 · 29% Range high $6
vs 200-day avg +8% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SER
Serina Therapeutics, Inc.
this stock
$63.25M +31.7% +132.1% — 0.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.72B +20.8% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +4.6% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +25.9% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
27
% held
5.5%
Net QoQ
-65.9K sh
Top holder
Sio Capital Management, L…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
145.5K
Days to cover
2.1d
Change
-77.4K sh
View
Short Volume
Short vol %
23%
As of
Aug 27, 2026
Short Total
View
Fails to Deliver
FTD shares
104
Value
$212
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
66.9%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$19.8K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Josh Gottheimer
Amount
$1.0K–$15.0K
Traded
Mar 10, 2026
View
Financials
Financials
Revenue (FY)
$130.0K
Net income (FY)
$-19.2M
EPS diluted
$-1.91
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 27, 2026
This year
16
View
Proposed Sales
Value
$279.4K
Shares
91.0K
Filed
Jan 20, 2026
View
Earnings & Events
Investor Relations
Latest news
Serina Therapeutics to Participat…
Published
Jul 24, 2026
View

Performance

Raw-price comparisons begin at the captured split on Mar 15, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
SER -4.9% +23.5% +64.7% +26.0% +31.7%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY -6.0% +19.6% +50.0% +22.8% +18.7%
Key facts CIK 1708599 CUSIP 81751A108 13F (30d) 22 filings 22 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)